References
- Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005;41:1955–68.
- Aftab N, Vieira A. Antioxidant activities of curcumin and combinations of this curcuminoid with other phytochemicals. Phytother Res 2010;24:500–2.
- Ak T, Gülçin İ. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008;174:27–37.
- Sunagawa Y, Morimoto T, Wada H, et al. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J 2011;75:2151–9.
- Thiyagarajan M, Sharma SS. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 2004;74:969–85.
- Moghadamtousi SZ, Kadir HA, Hassandarvish P, et al. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int 2014;2014:186864. doi: 10.1155/2014/186864.
- Perrone D, Ardito F, Giannatempo G, et al. Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med 2015;10:1615–23.
- Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:1–4.
- Yang K-Y, Lin L-C, Tseng T-Y, et al. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B 2007;853:183–9.
- Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013;7:41–55.
- Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull 2015;5:305–13.
- Jubeh TT, Barenholz Y, Rubinstein A. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res 2004;21:447–53.
- Takeuchi H, Matsui Y, Sugihara H, et al. Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs. Int J Pharm 2005;303:160–70.
- Fonte P, Andrade F, Araújo F, et al. Chapter fifteen - chitosan-coated solid lipid nanoparticles for insulin delivery. In: Nejat D, ed. Methods Enzymology. Burlington: Academic Press; 2012:295–314.
- Li H, Song J-H, Park J-S, Han K. Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm 2003;258:11–19.
- Seyfoddin A, Sherwin T, Patel DV, et al. Ex vivo and in vivo evaluation of chitosan coated nanostructured lipid carriers for ocular delivery of acyclovir. Curr Drug Deliv 2016;13:923–34.
- Weis C, Odermatt EK, Kressler J, et al. Poly(vinyl alcohol) membranes for adhesion prevention. J Biomed Mater Res Part B Appl Biomater 2004;70:191–202.
- Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J Control Release 2000;65:63–71.
- Yang M, Lai SK, Yu T, et al. Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol. J Control Release 2014;192:202–8.
- Ravi Kumar MNV. A review of chitin and chitosan applications. React Funct Polym 2000;46:1–27.
- Silva CA, Nobre TM, Pavinatto FJ, Oliveira ON. Jr. Interaction of chitosan and mucin in a biomembrane model environment. J Colloid Interface Sci 2012;376:289–95.
- Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007;337:299–306.
- McNeil-Watson F, Tscharnuter W, Miller J. A new instrument for the measurement of very small electrophoretic mobilities using phase analysis light scattering (PALS). Colloids Surf A 1998;140:53–7.
- Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47:165–96.
- Jenning V, Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN®). J Microencapsul 2001;18:149–58.
- Chandy T, Sharma CP. Chitosan-as a biomaterial. Biomater Artif Cells Artif Organs 1990;18:1–24.
- Hirano S, Seino H, Akiyama Y, Nonaka I. Chitosan: a biocompatible material for oral and intravenous administrations. In: Gebelein CG, Dunn RL, eds. Progress in biomedical polymers. Boston (MA): Springer US; 1990:283–90.
- Mansour HM, Sohn M, Al-Ghananeem A, DeLuca PP. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int J Mol Sci 2010;11:3298–322.
- Markovsky E, Baabur-Cohen H, Eldar-Boock A, et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release 2012;161:446–60.
- Filipovic-Grcic J, Skalko-Basnet N, Jalsenjak I. Mucoadhesive chitosan-coated liposomes: characteristics and stability. J Microencapsul 2001;18:3–12.
- Gref R, Lück M, Quellec P, et al. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B 2000;18:301–13.
- Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004;12:65–70.
- Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 2006;1:117–28.
- Boddupalli BM, Mohammed ZNK, Nath RA, Banji D. Mucoadhesive drug delivery system: an overview. J Adv Pharm Technol Res 2010;1:381–7.
- Wang Y-Y, Lai SK, Suk JS, et al. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier. Angew Chem Int Ed Engl 2008;47:9726–9.
- Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 1990;42:821–6.
- Jain S, Patil SR, Swarnakar NK, Agrawal AK. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol Pharm 2012;9:2626–35.
- Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995;16:215–33.
- Prego C, Torres D, Fernandez-Megia E, et al. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J Control Release 2006;111:299–308.
- Tobı´o M, Sánchez A, Vila A, et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B 2000;18:315–23.
- Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2:289–300.
- Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121–8.
- Nayak AP, Tiyaboonchai W, Patankar S, et al. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B 2010;81:263–73.
- Beloqui A, Memvanga PB, Coco R, et al. A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease. Colloids Surf B 2016;143:327–35.